

## CRISPR patent dispute is back in court. What should we expect?

It's baaaaack, that reputation-shredding, stock-moving fight to the death over key CRISPR patents. On [April 30] in Washington, D.C., the U.S. Court of Appeals for the Federal Circuit [heard] oral arguments in *University of California v. Broad Institute*. Questions?

**How did we get here?** The patent office ruled in February 2017 that the Broad's 2014 CRISPR patent on using CRISPR-Cas9 to edit genomes, based on discoveries by Feng Zhang, did not "interfere" with a patent application by UC based on the work of UC Berkeley's Jennifer Doudna.

...

**What's the morning line?** UC has its back to the wall. As in an appeal of a criminal case, this appeal is all about the law and whether the patent office interpreted and applied it correctly; there won't be any dramatic new evidence.

...

**Does UC have a shot?** Not much of one, said the experts consulted by STAT.

...

**When will we have a decision?** In as little as a week if the judges regard the case as meh, with no need to establish precedent and therefore write a long, complicated opinion. But that seems very unlikely...That probably means in 60 to 90 days.

**And then it's over, right?** The losing side will have at least 60 days to appeal to the Supreme Court, which would decide sometime after October whether or not to take the case.

**Read the full, original post:** [All you need to know for round 2 of the CRISPR patent fight](#)